Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-1120 alone and with pembrolizumab in advanced solid tumors
NCT04443088Phase 1Recruiting
- Sponsor
- Ionova Life Science
- Start
- Jun 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INV-1120 in solid tumor (advanced stage), sponsored by Ionova Life Science. Primary endpoints: Dose-Limiting Toxicities at 12 months and Recommended Phase 2 Dose at 12 months. Started Jun 2020; status: recruiting.
02
Drugs
INV-1120
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04443088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443088.